Pramlintide vs Tesamorelin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Pramlintide
Pramlintide (Symlin) is a synthetic analog of amylin, FDA-approved as an adjunct to insulin therapy in type 1 and type 2 diabetes. It helps control post-meal blood sugar spikes and promotes modest weight loss.
Full details →Tesamorelin
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.
Full details →Side-by-Side Comparison
| Aspect | Pramlintide | Tesamorelin |
|---|---|---|
| Dose Range | 15 mcg–120 mcg | 2 mg |
| Frequency | 3x daily | 1x daily |
| Cycle Length | 12–52 weeks | 8–52 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Mimics amylin's effects: slows gastric emptying, suppresses glucagon secretion after meals, and promotes satiety through central mechanisms. Complements insulin therapy. | Stimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue. |
| Typical Dosage | Type 1: Start 15mcg before meals, titrate to 30-60mcg. Type 2: Start 60mcg, may increase to 120mcg. Always with meal containing 30+ grams carbs or 250+ calories. | FDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules. |
| Administration | Subcutaneous injection immediately before major meals. Must reduce mealtime insulin by 50% when starting to prevent hypoglycemia. Never mix with insulin. | Subcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening. |
| Side Effects | Nausea (very common initially), headache, anorexia, vomiting, and abdominal pain. GI effects typically improve over time. | Common side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose. |
| Best For |
What They Have in Common
Pramlintide, Tesamorelin are both commonly used for:
Key Differences
Unique to Tesamorelin:
Which Has Stronger Evidence?
- Fat Loss: Tesamorelin has stronger research support.
| Goal | Pramlintide | Tesamorelin |
|---|---|---|
| Fat Loss | medium | high |
Key Studies
Pramlintide
- Chronic pramlintide decreases feeding via a reduction in meal size in male rats.
Peptides, 2024
- Pramlintide an Adjunct to Insulin Therapy: Challenges and Recent Progress in Delivery.
The Journal of pharmacology and experimental therapeutics, 2024
- Pramlintide for post-bariatric hypoglycaemia.
Diabetes, obesity & metabolism, 2022
Tesamorelin
- Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol.
BMJ open, 2026
- Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.
The Journal of infectious diseases, 2025
- Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.
AIDS (London, England), 2024
Ready to Learn More?
Looking for trusted sources?